A single low-dose CT scan may significantly reduce lung cancer-specific mortality, even in individuals not traditionally considered high-risk, according to promising new research presented at the 2026 European Lung Cancer Congress. The LUNG-CARE Project, a prospective study involving over 125,000 participants, demonstrated a substantial decrease in lung cancer deaths among those screened with low-dose CT compared to those receiving standard medical care. This finding challenges conventional screening guidelines, which typically focus on individuals with a history of heavy smoking or other established risk factors.
Lung cancer remains the leading cause of cancer death worldwide, and early detection is critical for improving survival rates. The American Cancer Society estimates that in 2024, over 234,000 Americans will be diagnosed with lung cancer, and approximately 125,070 will die from the disease. Current screening recommendations, largely based on the National Lung Screening Trial (NLST) published in 2011, prioritize individuals aged 50-80 with a 20 pack-year smoking history. However, a significant proportion of lung cancer cases occur in individuals with limited or no smoking history, highlighting the necessitate for broader screening strategies.
Expanding the Scope of Lung Cancer Screening
The LUNG-CARE Project, conducted between December 2015 and July 2021, enrolled 11,708 individuals who underwent a one-time low-dose CT screening and compared them to a control group of 114,392 individuals receiving routine medical care without systematic screening. Researchers found that low-dose CT screening was associated with a 55% reduction in lung cancer-specific mortality (HR, 0.45; 95% CI, 0.32-0.65; P < .001) across the entire study population. This benefit was particularly pronounced among women, with a hazard ratio of 0.28 (95% CI, 0.13-0.60; P < .001), suggesting potential sex-specific differences in screening effectiveness.
“The LUNG-CARE Project represents the first prospective non–risk-based lung cancer screening program,” explained study investigator Caichen Li, MD, from the First Affiliated Hospital of Guangzhou Medical University, in his presentation. “Compared with traditionally defined ‘high-risk’ individuals, ‘non–high-risk’ patients showed better survival and greater curative potential through early detection.” The study also revealed that patients whose cancers were detected through screening had significantly better overall survival, with a 5-year survival rate of 87% compared to 39% in those without screen-detected disease (HR, 0.13; 95% CI, 0.09-0.19; P < .001).
Who Benefits Most? A Look at the Data
Interestingly, the study found that individuals identified as “high-risk” based on NCCN and Chinese risk definitions still experienced worse survival outcomes (P < .001), suggesting that even within established risk categories, early detection through screening remains crucial. Researchers also identified respiratory comorbidities and heavy smoking as factors negatively impacting survival (P < .001). At baseline, a majority of participants in both the screening and non-screening groups were female (53.5% vs 53.4%), and a substantial proportion had no history of tobacco leverage (80.7% vs 69.2%). Among those diagnosed with lung cancer, the screening group had a higher proportion of stage I disease (81.5%) compared to the non-screening group (51.7%), indicating that screening led to earlier diagnoses.
Limitations and Future Directions
While the LUNG-CARE Project offers compelling evidence for the potential benefits of broader lung cancer screening, Dr. Li cautioned that the study’s non-randomized design introduces the possibility of confounding factors. “A limitation of the study is its non-randomized comparison with potential residual confounding,” he noted. Other limitations included imbalances in baseline characteristics between the groups, the potential for lead-time bias and overdiagnosis in the post-diagnosis survival analyses, and the study’s single-region, one-time screening design.
The study’s findings underscore the need for larger, randomized controlled trials to definitively assess the effectiveness of low-dose CT screening in non–high-risk populations. Researchers are also exploring the potential of incorporating biomarkers and artificial intelligence to refine risk stratification and personalize screening recommendations. The baseline lung cancer detection rate of 1.9% for in situ and minimally invasive disease, and 1.4% for invasive adenocarcinoma, was comparable to rates observed in other high-risk screening studies, such as the TALENT and NLST trials. The NLST, published in 2011, was instrumental in establishing the current screening guidelines.
Understanding Low-Dose CT Scans
Low-dose CT scans use X-rays to create detailed images of the lungs. The radiation dose is significantly lower than that of a standard chest CT scan, minimizing potential risks. The procedure is non-invasive and typically takes only a few minutes to complete.
The LUNG-CARE Project’s findings are likely to fuel ongoing debate about optimal lung cancer screening strategies. As Dr. Li emphasized, further research is essential to determine the most effective and cost-efficient approach to early detection and reducing the burden of this devastating disease.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. We see essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The next step for the LUNG-CARE Project team is to analyze long-term follow-up data and to advocate for the initiation of randomized controlled trials to validate these findings. Further research will be critical to refine screening protocols and ensure that the benefits of early detection are realized for a wider population.
What are your thoughts on expanding lung cancer screening? Share your comments below, and please share this article with anyone who might find it helpful.
Keep reading
